ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PYC Physiomics Plc

1.15
-0.05 (-4.17%)
17 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Physiomics Plc LSE:PYC London Ordinary Share GB00BDR6W943 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.05 -4.17% 1.15 1.10 1.20 1.20 1.15 1.20 216,341 08:44:37
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 597k -477k -0.0035 -3.29 1.56M
Physiomics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker PYC. The last closing price for Physiomics was 1.20p. Over the last year, Physiomics shares have traded in a share price range of 0.925p to 3.15p.

Physiomics currently has 135,472,478 shares in issue. The market capitalisation of Physiomics is £1.56 million. Physiomics has a price to earnings ratio (PE ratio) of -3.29.

Physiomics Share Discussion Threads

Showing 27101 to 27109 of 30125 messages
Chat Pages: Latest  1085  1084  1083  1082  1081  1080  1079  1078  1077  1076  1075  1074  Older
DateSubjectAuthorDiscuss
29/9/2020
20:45
BROKERS name aim top picks -
postme
29/9/2020
20:35
Value smashes piggy AGAIN lol
notknowing
29/9/2020
19:47
I m optimistic about q4 ,I double my investment this week .by Xmas time I am expecting 14p min .Dyor
tmmalik
29/9/2020
18:18
Woo hoo a E365m result for our client Merck KGaA today

Wonder how they might spend their winnings on R&D and their partners ?

Darmstadt, September 29, 2020. In the United States Merck KGaA's subsidiary EMD Serono, Inc. (Merck) is involved in a US patent dispute with Biogen Inc., United States (Biogen). Biogen sued Merck for damages in connection with a patent infringement caused by Merck's product Rebif before the U.S. District Court New Jersey, Newark. Merck defended itself against the allegations and brought a countersuit claiming that Biogen's patent is invalid. In February 2018 a jury declared Biogen's patent invalid vis-à-vis Merck. The jury verdict was overturned by the District Court Judge, who upheld the validity of Biogen's patent. Merck filed a complaint with the U.S. Court of Appeals for the Federal Circuit against this ruling.

On 28 September 2020 the U.S. Court of Appeals for the Federal Circuit set aside the decision of the District Court Judge, invalidated Biogen's patent and instructed the District Court to reinstate the jury verdict.

Therefore, Merck KGaA has decided today to reverse the provisions for the patent dispute proceedings in the amount of EUR 365 million. Thereof, up to a mid to high double-digit million amount might be booked into the financial result.
Merck KGaA will adjust its forecasts accordingly as part of its regular financial reporting

the stigologist
29/9/2020
17:05
How you feeling stig,foolish comes to mind.
albert3591
29/9/2020
16:20
A lot of unhappy people tomorrow I feel.
albert3591
29/9/2020
16:07
Looks like no ones falling for the ramps now,even stiggy has given up.
albert3591
29/9/2020
14:34
Stig

They only time PYC did anything was a few years ago when the E Cig chap up here in Accrington pumped the hell out of it and added a few quid to his millions ha.

412069
29/9/2020
14:22
PFC and CPI looking good Maddie.
notknowing
Chat Pages: Latest  1085  1084  1083  1082  1081  1080  1079  1078  1077  1076  1075  1074  Older

Your Recent History

Delayed Upgrade Clock